| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| XERSXeris Biopharma Holdings, Inc. | 1.26B | 7.58 | -20.49 | 23.89% | -5.88% |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.07M | 1.56M | 2.46M | 2.72M | 20.43M | 49.59M | 110.25M | 163.91M | 203.07M |
| Revenue Growth % | - | 0.45% | 0.58% | 0.1% | 6.51% | 1.43% | 1.22% | 0.49% | 0.24% |
| Cost of Goods Sold | 8K | 4K | 42K | 1.6M | 9.33M | 13.32M | 22.63M | 28.64M | 36.83M |
| COGS % of Revenue | 0.01% | 0% | 0.02% | 0.59% | 0.46% | 0.27% | 0.21% | 0.17% | 0.18% |
| Gross Profit | 1.07M | 1.55M | 2.42M | 1.12M | 11.11M | 36.27M | 87.61M | 135.27M | 166.24M |
| Gross Margin % | 0.99% | 1% | 0.98% | 0.41% | 0.54% | 0.73% | 0.79% | 0.83% | 0.82% |
| Gross Profit Growth % | - | 0.45% | 0.56% | -0.54% | 8.93% | 2.27% | 1.42% | 0.54% | 0.23% |
| Operating Expenses | 14.3M | 28.18M | 61.77M | 123.5M | 94.65M | 151.43M | 169.55M | 179.28M | 199.88M |
| OpEx % of Revenue | 13.3% | 18.11% | 25.06% | 45.37% | 4.63% | 3.05% | 1.54% | 1.09% | 0.98% |
| Selling, General & Admin | 4.06M | 8.02M | 21.11M | 63.06M | 73.73M | 125.72M | 137.75M | 146.09M | 163.48M |
| SG&A % of Revenue | 3.78% | 5.15% | 8.57% | 23.17% | 3.61% | 2.54% | 1.25% | 0.89% | 0.81% |
| Research & Development | 10.24M | 20.17M | 40.65M | 60.44M | 20.92M | 25.16M | 20.97M | 22.34M | 25.56M |
| R&D % of Revenue | 9.52% | 12.96% | 16.49% | 22.2% | 1.02% | 0.51% | 0.19% | 0.14% | 0.13% |
| Other Operating Expenses | -5K | -1K | 0 | 0 | 0 | 550K | 10.84M | 10.84M | 10.84M |
| Operating Income | -13.23M | -26.63M | -59.34M | -122.38M | -83.55M | -115.16M | -81.94M | -44.01M | -33.65M |
| Operating Margin % | -12.31% | -17.11% | -24.07% | -44.96% | -4.09% | -2.32% | -0.74% | -0.27% | -0.17% |
| Operating Income Growth % | - | -1.01% | -1.23% | -1.06% | 0.32% | -0.38% | 0.29% | 0.46% | 0.24% |
| EBITDA | -13.12M | -26.45M | -59.02M | -121.3M | -82.08M | -113.28M | -69.27M | -30.85M | -21.02M |
| EBITDA Margin % | -12.2% | -17% | -23.94% | -44.56% | -4.02% | -2.28% | -0.63% | -0.19% | -0.1% |
| EBITDA Growth % | - | -1.02% | -1.23% | -1.06% | 0.32% | -0.38% | 0.39% | 0.55% | 0.32% |
| D&A (Non-Cash Add-back) | 116K | 177K | 320K | 1.08M | 1.47M | 1.88M | 12.67M | 13.16M | 12.63M |
| EBIT | -13.21M | -26.55M | -57.53M | -118.88M | -80.59M | -115.55M | -81.98M | -36.9M | -26.62M |
| Net Interest Income | 3K | 122K | -932K | -4.35M | -2.9M | -6.87M | -11.52M | -21.86M | -27.85M |
| Interest Income | 5K | 124K | 1.61M | 2.81M | 4.46M | 313K | 2.58M | 4.75M | 5.32M |
| Interest Expense | 2K | 2K | 2.54M | 7.16M | 7.36M | 7.18M | 14.1M | 26.61M | 33.17M |
| Other Income/Expense | 22K | 75K | -736K | -3.66M | -7.7M | -7.57M | -14.14M | -19.49M | -23.46M |
| Pretax Income | -13.21M | -26.55M | -60.08M | -126.04M | -91.25M | -122.72M | -96.08M | -63.5M | -57.1M |
| Pretax Margin % | -12.29% | -17.07% | -24.37% | -46.3% | -4.47% | -2.47% | -0.87% | -0.39% | -0.28% |
| Income Tax | -3K | 1K | 0 | -458K | -110K | 0 | -1.42M | -1.25M | -2.27M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 0.99% | 0.98% | 0.96% |
| Net Income | -13.21M | -26.55M | -60.08M | -125.58M | -91.14M | -122.72M | -94.66M | -62.26M | -54.84M |
| Net Margin % | -12.29% | -17.07% | -24.37% | -46.14% | -4.46% | -2.47% | -0.86% | -0.38% | -0.27% |
| Net Income Growth % | - | -1.01% | -1.26% | -1.09% | 0.27% | -0.35% | 0.23% | 0.34% | 0.12% |
| Net Income (Continuing) | -13.21M | -26.55M | -60.08M | -125.58M | -91.14M | -122.72M | -94.66M | -62.26M | -54.84M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -7.17 | -13.09 | -4.99 | -3.49 | -2.14 | -1.55 | -0.70 | -0.45 | -0.37 |
| EPS Growth % | - | -0.83% | 0.62% | 0.3% | 0.39% | 0.28% | 0.55% | 0.36% | 0.18% |
| EPS (Basic) | -7.17 | -13.09 | -4.99 | -3.49 | -2.14 | -1.55 | -0.70 | -0.45 | -0.37 |
| Diluted Shares Outstanding | 1.84M | 2.03M | 12.05M | 26.11M | 42.64M | 79.03M | 135.63M | 137.67M | 146.77M |
| Basic Shares Outstanding | 1.84M | 2.03M | 12.05M | 26.11M | 42.64M | 79.03M | 135.63M | 137.67M | 146.77M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 33.17M | 44.05M | 117.9M | 87.48M | 152.21M | 142.6M | 186.82M | 156.26M | 167.66M |
| Cash & Short-Term Investments | 32.27M | 42.05M | 112.63M | 75.55M | 133.79M | 102.43M | 121.97M | 72.45M | 71.62M |
| Cash Only | 32.27M | 42.05M | 45.72M | 19.52M | 37.6M | 67.27M | 121.97M | 67.45M | 71.62M |
| Short-Term Investments | 0 | 0 | 66.92M | 56.03M | 96.19M | 35.16M | 0 | 5M | 0 |
| Accounts Receivable | 101K | 1.2M | 2.87M | 4.69M | 6.88M | 17.46M | 30.83M | 39.2M | 40.41M |
| Days Sales Outstanding | 34.29 | 281.26 | 424.82 | 629.3 | 122.8 | 128.48 | 102.07 | 87.28 | 72.64 |
| Inventory | 0 | 0 | 0 | 2.18M | 8.35M | 18.12M | 24.73M | 38.84M | 48.17M |
| Days Inventory Outstanding | - | - | - | 495.47 | 326.85 | 496.55 | 398.88 | 494.88 | 477.41 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 9.29M | 5.78M | 7.45M |
| Total Non-Current Assets | 359K | 945K | 2.13M | 21.5M | 6.94M | 161.76M | 157.7M | 166.34M | 155.4M |
| Property, Plant & Equipment | 312K | 788K | 2.03M | 7.85M | 6.71M | 6.63M | 9.51M | 29.18M | 28.21M |
| Fixed Asset Turnover | 3.45x | 1.97x | 1.21x | 0.35x | 3.05x | 7.48x | 11.60x | 5.62x | 7.20x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 22.86M | 22.86M | 22.86M | 22.86M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 131.45M | 120.61M | 109.76M | 98.92M |
| Long-Term Investments | 0 | 0 | 0 | 13.23M | 0 | 0 | 0 | 0 | 4.12M |
| Other Non-Current Assets | 47K | 157K | 95K | 420K | 232K | 829K | 4.73M | 4.54M | -4.81M |
| Total Assets | 33.53M | 45M | 120.03M | 108.99M | 159.15M | 304.36M | 344.52M | 322.6M | 323.06M |
| Asset Turnover | 0.03x | 0.03x | 0.02x | 0.02x | 0.13x | 0.16x | 0.32x | 0.51x | 0.63x |
| Asset Growth % | - | 0.34% | 1.67% | -0.09% | 0.46% | 0.91% | 0.13% | -0.06% | 0% |
| Total Current Liabilities | 2.53M | 4.86M | 10.17M | 27.34M | 28.21M | 79.04M | 73.62M | 95.19M | 100.44M |
| Accounts Payable | 1.31M | 1.98M | 866K | 5.6M | 3.12M | 8.92M | 4.61M | 11.56M | 2.29M |
| Days Payables Outstanding | 60K | 180.31K | 7.53K | 1.28K | 121.97 | 244.58 | 74.28 | 147.36 | 22.69 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.1M |
| Deferred Revenue (Current) | 263K | 234K | 232K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 468K | 1.3M | 4.98M | 9.06M | 11.2M | 25.63M | 27.23M | 51.43M | 39.75M |
| Current Ratio | 13.13x | 9.06x | 11.59x | 3.20x | 5.40x | 1.80x | 2.54x | 1.64x | 1.67x |
| Quick Ratio | 13.13x | 9.06x | 11.59x | 3.12x | 5.10x | 1.57x | 2.20x | 1.23x | 1.19x |
| Cash Conversion Cycle | - | - | - | -151.02 | 327.68 | 380.46 | 426.67 | 434.8 | 527.36 |
| Total Non-Current Liabilities | 62.94M | 97.97M | 34.45M | 67.21M | 97.18M | 130.09M | 225.71M | 234.19M | 252.23M |
| Long-Term Debt | 0 | 0 | 31.89M | 58.3M | 87.02M | 88.07M | 187.07M | 190.93M | 217.01M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 9.4M | 34.76M | 33.26M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 4.94M | 3.52M | 2.27M | 0 |
| Other Non-Current Liabilities | 62.94M | 97.97M | 2.56M | 8.91M | 10.16M | 37.08M | 25.72M | 6.23M | 1.97M |
| Total Liabilities | 65.47M | 102.83M | 44.62M | 94.55M | 125.39M | 209.13M | 299.33M | 329.38M | 352.68M |
| Total Debt | 0 | 0 | 31.89M | 58.3M | 87.02M | 88.07M | 198.06M | 229.19M | 271.45M |
| Net Debt | -32.27M | -42.05M | -13.83M | 38.79M | 49.42M | 20.8M | 76.09M | 161.74M | 199.83M |
| Debt / Equity | - | - | 0.42x | 4.04x | 2.58x | 0.92x | 4.38x | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -6615.50x | -13314.50x | -23.32x | -17.09x | -11.35x | -16.04x | -5.81x | -1.65x | -1.01x |
| Total Equity | -31.93M | -57.83M | 75.41M | 14.44M | 33.76M | 95.23M | 45.19M | -6.78M | -29.61M |
| Equity Growth % | - | -0.81% | 2.3% | -0.81% | 1.34% | 1.82% | -0.53% | -1.15% | -3.37% |
| Book Value per Share | -17.33 | -28.51 | 6.26 | 0.55 | 0.79 | 1.21 | 0.33 | -0.05 | -0.20 |
| Total Shareholders' Equity | -31.93M | -57.83M | 75.41M | 14.44M | 33.76M | 95.23M | 45.19M | -6.78M | -29.61M |
| Common Stock | 1K | 1K | 2K | 3K | 6K | 13K | 14K | 14K | 15K |
| Retained Earnings | -34.03M | -60.59M | -120.67M | -246.25M | -337.38M | -460.11M | -554.77M | -617.02M | -671.86M |
| Treasury Stock | -2.1M | -2.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -268K | -440K | -52K | 43K | 6K | -31K | -23K | -25K | -25K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -16.09M | -24.66M | -56.28M | -80.56M | -80.56M | -95.53M | -102.89M | -47.02M | -36.98M |
| Operating CF Margin % | -14.96% | -15.85% | -22.83% | -29.6% | -3.94% | -1.93% | -0.93% | -0.29% | -0.18% |
| Operating CF Growth % | - | -0.53% | -1.28% | -0.43% | 0% | -0.19% | -0.08% | 0.54% | 0.21% |
| Net Income | -13.21M | -26.55M | -60.08M | -91.14M | -91.14M | -122.72M | -94.66M | -62.26M | -54.84M |
| Depreciation & Amortization | 116K | 177K | 320K | 1.47M | 1.47M | 1.88M | 12.67M | 13.16M | 12.63M |
| Stock-Based Compensation | 540K | 499K | 1.73M | 6.48M | 8.27M | 11.38M | 12.16M | 10.72M | 18.36M |
| Deferred Taxes | 0 | 0 | -414K | 536K | 1.11M | -1.42M | -1.42M | -1.25M | -2.27M |
| Other Non-Cash Items | 49K | 94K | 560K | 4.89M | 39K | 3.5M | 3.52M | -1.1M | -2.04M |
| Working Capital Changes | -3.58M | 1.12M | 1.61M | -2.8M | -312K | 11.85M | -35.15M | -6.29M | -8.82M |
| Change in Receivables | 204K | -1.1M | -1.67M | -2.18M | -6.24M | -13.37M | -13.37M | -8.37M | -1.22M |
| Change in Inventory | -846K | 1.7M | 4.04M | -5.14M | -7.42M | -7.46M | -7.46M | -14.8M | -8.78M |
| Change in Payables | -2.91M | 661K | -1.11M | -2.49M | 5.53M | -4.32M | -4.32M | 6.96M | -9.61M |
| Cash from Investing | -35K | -700K | -68.26M | -27.41M | -27.41M | 34.46M | 34.46M | -6M | 4.88M |
| Capital Expenditures | -35K | -700K | -1.51M | -377K | -377K | -524K | -524K | -2.26M | -868K |
| CapEx % of Revenue | 0.03% | 0.45% | 0.61% | 0.14% | 0.02% | 0.01% | 0% | 0.01% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -66.75M | -377K | 0 | 4.55M | 0 | 0 | 0 |
| Cash from Financing | 3.9M | 35.14M | 128.21M | 126.06M | 126.06M | 27.25M | 127.47M | -1.61M | 36.17M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | -64K | -336K | -333K | 101.06M | -9.51M | 0 | -4.78M | -604K | 1.73M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -16.12M | -25.36M | -57.79M | -80.94M | -96.62M | -103.42M | -103.42M | -49.29M | -37.85M |
| FCF Margin % | -15% | -16.3% | -23.44% | -29.73% | -4.73% | -2.09% | -0.94% | -0.3% | -0.19% |
| FCF Growth % | - | -0.57% | -1.28% | -0.4% | -0.19% | -0.07% | 0% | 0.52% | 0.23% |
| FCF per Share | -8.75 | -12.51 | -4.80 | -3.10 | -2.27 | -1.31 | -0.76 | -0.36 | -0.26 |
| FCF Conversion (FCF/Net Income) | 1.22x | 0.93x | 0.94x | 0.64x | 0.88x | 0.78x | 1.09x | 0.76x | 0.67x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.95M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -683.66% | -279.56% | -378.2% | -190.28% | -134.83% | -324.2% | - |
| Return on Invested Capital (ROIC) | - | - | - | -159.9% | -91.87% | -86.71% | -51.79% | -23.9% | -15.52% |
| Gross Margin | 99.26% | 99.74% | 98.3% | 41.11% | 54.35% | 73.14% | 79.47% | 82.52% | 81.86% |
| Net Margin | -1228.74% | -1706.56% | -2437.32% | -4613.52% | -446% | -247.48% | -85.86% | -37.98% | -27% |
| Debt / Equity | - | - | 0.42x | 4.04x | 2.58x | 0.92x | 4.38x | - | - |
| Interest Coverage | -6615.50x | -13314.50x | -23.32x | -17.09x | -11.35x | -16.04x | -5.81x | -1.65x | -1.01x |
| FCF Conversion | 1.22x | 0.93x | 0.94x | 0.64x | 0.88x | 0.78x | 1.09x | 0.76x | 0.67x |
| Revenue Growth | - | 44.74% | 58.42% | 10.43% | 650.73% | 142.67% | 122.32% | 48.68% | 23.89% |
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Product | 109.26M | 153.36M | 196.64M |
| Product Growth | - | 40.36% | 28.22% |
| Keveyis | 49.31M | 56.77M | 49.53M |
| Keveyis Growth | - | 15.14% | -12.76% |
Xeris Biopharma Holdings, Inc. (XERS) reported $266.1M in revenue for fiscal year 2024. This represents a 24657% increase from $1.1M in 2016.
Xeris Biopharma Holdings, Inc. (XERS) grew revenue by 23.9% over the past year. This is strong growth.
Xeris Biopharma Holdings, Inc. (XERS) reported a net loss of $15.6M for fiscal year 2024.
Xeris Biopharma Holdings, Inc. (XERS) generated $19.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.